Five patient organizations will receive funds to implement plans aimed at reducing health disparities, connecting people living with systemic lupus erythematosus (SLE) and lupus nephritis (LN) with needed health management resources

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the Company) today announced the recipients of five $50,000 grant awards to support implementation patient navigation programs targeted toward disadvantaged populations at most risk of developing SLE and LN. Each non-profit patient-focused organization will receive funds to support their proposed one-year pilot programs with the goal of helping people living with these conditions to navigate the complexities of diagnosis and disease management, support better adherence to medical appointments and treatments, and provide customized resources and education.

"The RFP process was competitive, and we were pleased to receive so many thoughtful and creative submissions for this first-ever Aurinia initiative," said Christine Lindsay, Vice President, Professional and Advocacy Relations. "The five recipients were awarded grants based on their demonstrated ability to collaborate with key lupus centers, rheumatologists, and nephrologists, their ability to measure program outcomes, and ultimately, provide individualized support to underserved populations."

Navigation programs will be launched in the following cities:

  • Atlanta, Georgia
    Lupus Foundation of America Georgia Chapter in collaboration with the Grady Lupus Clinic
  • Brooklyn, New York
    The Health Science Center of Brooklyn Foundation in collaboration with SUNY Downstate Health Sciences University
  • Cleveland, Ohio
    Lupus Foundation of America Ohio Chapter in collaboration with the Ohio Department of Health
  • Indianapolis, Indiana
    Lupus Foundation of America Indiana Chapter in collaboration with Eskenazi
    Hospital, Lupus Clinic, and Indiana University Hospital
  • Philadelphia, Pennsylvania
    Lupus Foundation of America Tri-State Chapter in collaboration with Temple University Hospital Lupus Program

"The need for a patient navigator program at our institution, and many like ours, is enormous. It has long been recognized that racial and ethnic characteristics influence outcome in patients with SLE. Black (African American and Afro-Caribbean) and Hispanic SLE patients have more severe disease than white patients, with higher mortality and a more rapid accrual of irreversible damage," says Ellen M. Ginzler MD, MPH, Vice Chair for Research, Department of Medicine Chief, Rheumatology Division, SUNY Downstate Health Science University. "We are pleased and honored to work with The Health Science Center of Brooklyn Foundations to implement a student-led navigator program and to work to reduce health disparities, stressing early diagnosis, and providing compassionate high quality care to immigrant, at-risk, and underserved individuals."

"Twenty years ago, very few spoke of lupus. There was little awareness and understanding of the signs and symptoms and very little investment in research. We have made great progress, but we must do more as we have lost too many too early of all ages, and we cannot rest," states Sam Lim, MD, MPH, Professor of Medicine and Epidemiology, Emory University, Chief of Rheumatology – Grady Health System, and Director of the Grady Lupus Clinic. "We are eager to work with the Lupus Foundation of America, Georgia chapter, to implement a patient navigator program that will mitigate the barriers to health equity by improving patient adherence to treatment, provider-patient communication, patient mental and physical health, and, most importantly, outcomes."

Aurinia funded patient navigator programs launch on July 1 and grant recipients will convene regularly to share lessons learned, best practices, and community needs that can be addressed through navigation services throughout the 1-year grant period.

About systemic lupus erythematosus (SLE) and lupus nephritis (LN)

LN is a serious manifestation of SLE, a chronic and complex autoimmune disease. Approximately one out of three of these individuals with SLE will develop LN. If poorly controlled, LN can lead to permanent and irreversible tissue damage within the kidney, resulting in kidney failure. Black and Asian individuals with SLE are four times more likely to develop LN and individuals of Hispanic ancestry are approximately twice as likely to develop the disease when compared with Caucasian individuals. Black and Hispanic individuals with SLE also tend to develop LN earlier and have poorer outcomes when compared to Caucasian individuals.

About Aurinia

Aurinia Pharmaceuticals, Inc. is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company's head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

Glenn Schulman, PharmD, MPH
Investor Relations & Corporate Communications, Aurinia

Dana Lynch
Corporate Communications, Aurinia

News Provided by Business Wire via QuoteMedia

Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines

- Public-Private Effort to Shift Traditional Model of Hepatitis Management to Primary Care and Help to Expand Care to More People in Need -

Gilead Sciences, Inc. today announced a new public-private initiative with the Partnership for Health Advancement in Vietnam (HAIVN), a collaboration between Brigham and Women's Hospital, Harvard Medical School and Beth Israel Deaconess Medical Center. This multi-year initiative will have a phased approach to help address barriers that limit viral hepatitis diagnosis and care at primary healthcare facilities in Vietnam and the Philippines, two countries with high burdens of hepatitis B and C.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

The Forces of Beauty® Report from The DREAM Initiative® Reveals Demand for New Standards of Beauty and Imagery

--Initiative Creates Groundbreaking New, Royalty Free Inclusive Image Gallery In Strategic Partnership with Shutterstock Studios--

Today, Allergan Aesthetics, an ABBVie company (NYSE: ABBV), and skinbetter science ® announce a new report from their DREAM (Driving Racial Equity in Aesthetic Medicine) Initiative ® along with a long-term partnership with Shutterstock Studios. The report, titled Forces of Beauty ® provides a new understanding of what inclusive and representative beauty looks like today by shedding light on how narrowly defined Eurocentric ideals continue to impact women of color. By surveying over 4,000 women aged 21-65, from multiple geographic locations and backgrounds, the report explores what defines beauty, how beauty impacts women's lives, and the interplay between beauty and race. Some key insights include:

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
The Gummy Project Expands in US After Receiving Purchase Order from 5-Star Luxury Four Seasons Hotel San Francisco to Become Supplier of Gummy Products for Guest Room Mini-Bars

The Gummy Project Expands in US After Receiving Purchase Order from 5-Star Luxury Four Seasons Hotel San Francisco to Become Supplier of Gummy Products for Guest Room Mini-Bars

  • The Gummy Project's Peachy Bees and Watermelon Sharks expected to be featured for sale in all 277 guest rooms at the 5-star luxury Four Seasons Hotel San Francisco
  • Purchase order from world class hotel marks the achievement of another milestone in The Gummy Project's ongoing multi-channel sales strategy

The Gummy Project (CSE: GUMY) (FSE: 0OS) (OTCQB: GUMYF) ("GUMY" or the "Company") is pleased to announce that it has received a purchase order from the 5-star luxury Four Seasons Hotel San Francisco to become a supplier of gummies for each of the hotel's 277 guest room mini-bars.

"We are thrilled to continue our strategic expansion in the US and honoured to have been selected by the luxury 5-star Four Seasons Hotel San Francisco to be a supplier of Peachy Bees and Watermelon sharks for hotel guest rooms," said Charlie Lamb, President & CEO of GUMY. "We very much look forward to developing a long-term relationship with The Four Seasons Hotel San Francisco, who not only are a world class hotel but who also share our commitment to a more sustainable future for everyone."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Komo Plant Based Foods Expands Distribution through Quality Foods Grocery Chain

Komo Plant Based Foods Expands Distribution through Quality Foods Grocery Chain

Komo Plant Based Foods Inc. (CSE:YUM) (OTCQB:KOMOF) (FRA:9HB) ("Komo") is pleased to announce Quality Foods will be carrying Komo's 2 serving Lasagna, Shepherd's Pie and Mac & Greens as well as both Meal Helpers (Bolognese and Taco Filling) at all Quality Foods locations

Quality Foods is a British Columbia owned, award-winning leader in the Canadian grocery industry with brick and mortar stores in 13 locations in B.C. including Qualicum Foods in Qualicam Beach, Quality Foods in Parksville, Nanoose Bay, Nanaimo (Harewood), Nanaimo (Northridge Village), Port Alberni, Comox, Courtenay, Campbell River, Powell River, Victoria (Langford) and Victoria (View Royal).

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Gilead Sciences Completes Acquisition of MiroBio

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire MiroBio, a privately held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, for approximately $405 million in cash. The acquisition provides Gilead with MiroBio's proprietary discovery platform and entire portfolio of immune inhibitory receptor agonists. MiroBio's lead investigational antibody, MB272, is a selective agonist of immune inhibitory receptor B- and T-Lymphocyte Attenuator (BTLA) and has entered Phase 1 clinical trials, with the first patient dosed in early August 2022. MB272 targets T, B and dendritic cells to inhibit or blunt activation and suppress an inflammatory immune response.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology Convergence 2022

Five abstracts underscore the long-term safety and efficacy of voclosporin, including in Latino patients and patients with Class V lupus nephritis

Data presentation on pre-clinical asset AUR200 reinforces Aurinia's commitment to autoimmune disease

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News